BioCentury | Nov 27, 2019
Company News

Nov. 27 Company Quick Takes: Orexo, GAIA in second deal for substance abuse digital therapy; plus PDUFA date for Verrica's skin infection candidate and $25M fol

Orexo gets U.S. rights to GAIA's alcohol abuse digital therapeutic Orexo AB (SSE:ORX) licensed exclusive U.S. rights from GAIA AG to vorvida, a digital therapeutic to treat alcohol use disorder; financial terms are undisclosed. Orexo...
BioCentury | Aug 21, 2019
Company News

Orexo, GAIA to develop digital therapeutic for opioid use disorder

Via a deal with German digital therapeutics company GAIA, Orexo will develop a psychosocial support product intended to enhance the use of Zubsolv buprenorphine/naloxone, its treatment for opioid use disorder (OUD). For its first digital...
BioCentury | Apr 12, 2019
Product Development

Changing models and minds to improve access to addiction treatment

A lack of acknowledgment by key stakeholders in the healthcare system that medications can treat opioid abuse, along with a fragmented reimbursement system, means that effective treatments aren’t getting to the majority of patients who...
BioCentury | Apr 10, 2019
Company News

U.S. fraud charges pummel Indivior shares

Indivior fell 75.90p (72%) to 30.05p on Wednesday after the U.S. Department of Justice indicted the company for allegedly defrauding providers and payers to increase prescriptions of its opioid dependence drug Suboxone sublingual film. Wednesday's...
BioCentury | Apr 5, 2019
Product Development

Reaching addiction patients where they’re at

Coming at the opioid crisis from two different angles, NIH’s National Institute on Drug Abuse and Alkermes plc have concluded that ending the epidemic will mean developing ways of getting medication to patients who fall...
BioCentury | Feb 22, 2019
Company News

Generic Suboxone products enter U.S. market

At least three companies have launched in the U.S. generic versions of opioid dependence drug Suboxone buprenorphine/naloxone sublingual film from Indivior plc (LSE:INDV). The generic Suboxone manufacturers include Alvogen Inc. (Pinebrook, N.J.), the Sandoz unit...
BioCentury | Feb 15, 2019
Company News

Indivior divests Suboxone tablets to China’s Zhejiang Pukang

Indivior plc (LSE:INDV) will sell Chinese rights to its sublingual tablet formulation of Suboxone buprenorphine/naloxone to Zhejiang Pukang Biotechnology Co. Ltd. (Hangzhou, China) so that Indivior can focus on long-term growth of its extended release...
BioCentury | Dec 21, 2018
Company News

Orexo regains ex-U.S. rights to Zubsolv from Mundipharma

Orexo AB (SSE:ORX) will regain global, ex-U.S. rights to Zubsolv buprenorphine/naloxone from Mundipharma International Ltd. (Dublin, Ireland), effective April 13. Orexo, which holds U.S. rights to the drug, said the news follows a portfolio reorganization...
BioCentury | Nov 30, 2018
Company News

Dr. Reddy's gets green light to market opioid dependence generic

Dr. Reddy's Laboratories Ltd. (NYSE:RDY) said on Nov. 20 that a U.S. federal court vacated a district court's preliminary decision that prohibited the company from selling its generic version of film Suboxone buprenorphine/naloxone sublingual from...
BioCentury | Sep 14, 2018
Company News

ICER finds opioid use disorder treatments not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of...
Items per page:
1 - 10 of 133